BIOTECH
BIOTECH
STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision...
Read more
BIOTECH
AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V
The transaction reflects a pre-money equity value of $400 million for AUM Biosciences Transaction is...
Read more
BIOTECH
Stalicla SA and Evgen Pharma plc ink $160.5m licensing deal for SFX-01
Precision neuroscience company Stalicla SA has licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders...
Read more
BIOTECH
AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTRK Fusion Gene
SINGAPORE and BETHESDA, Md., Aug. 18, 2022 (GLOBE NEWSWIRE) — AUM Biosciences, a global clinical-stage...
Read more
BIOTECH
Treos Bio Announces First Patient Dosed in Phase 2 Trial of PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor for the Treatment of Metastatic Colorectal Cancer
LONDON, June 27, 2022 (GLOBE NEWSWIRE) — Treos Bio Limited (“Treos”), a clinical stage biotechnology...
Read more